Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 854, Issue -, Pages 54-61Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2019.03.055
Keywords
Asymmetric dimethylarginine; Dimethylarginine dimethylaminohydrolase; Tissue fibrosis
Categories
Funding
- National Natural Science Foundation of China [81673432]
- Hunan Provincial Natural Science Foundation of China [2018JJ2543]
Ask authors/readers for more resources
Fibrosis is a reparative process with very few therapeutic options to prevent its progression to organ dysfunction. Chronic fibrotic diseases contribute to an estimated 45% of all death in the industrialized world. Asymmetric dimethylarginine (ADMA), an endothelial nitric oxide synthase inhibitor, plays a crucial role in the pathogenesis of various cardiovascular diseases associated with endothelial dysfunction. Recent reports have focused on ADMA in the pathogenesis of tissue fibrosis. This review discusses the current knowledge about ADMA biology, its association with risk factors of established fibrotic diseases and the potential pathophysiological mechanisms implicating ADMA in the process of tissue fibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available